Clinical Trial Update: A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the safety and effects of ritlecitinib in nonsegmental vitiligo is currently recruiting. The sponsor is Pfizer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vitiligo

Drugs mentioned

• Ritlecitinib (ritlecitinib)

Snippet

Sponsor: Pfizer | Conditions: Vitiligo | Phase 3 | Status: RECRUITING